根治性前列腺切除术前强化雄激素剥夺治疗评估:恩扎卢胺联合亮丙瑞林加或不加阿比特龙的随机II期试验
这项II期随机试验在75例局部晚期前列腺癌患者中比较了术前24周恩扎卢胺联合亮丙瑞林(EL)加或不加阿比特龙和泼尼松(ELAP)的疗效。ELAP组病理完全缓解或微小残留病率为30%(15/50),EL组为16%(4/25),差异无统计学意义(双侧P=0.263)。治疗耐受良好,ELAP有改善病理结局的趋势,需更长随访评估复发影响。
要点
- ELAP组病理完全缓解或微小残留病率30%(15/50),EL组16%(4/25),双侧P=0.263,无显著差异。
- 两组ypT3疾病、切缘阳性和淋巴结阳性率相似,治疗耐受良好。
- 肿瘤ERG阳性和PTEN缺失与更广泛的残留肿瘤相关,需进一步研究。
核心结论
- 局部晚期前列腺癌术前新辅助激素治疗使部分患者获得良好病理缓解,ELAP有改善病理结局的趋势。
- 需更长随访评估治疗对复发率的影响。
- ERG和PTEN改变与更差结局的潜在关联需额外研究。
研究设计与样本
- 随机II期试验,纳入活检Gleason评分≥4+3=7、PSA>20 ng/mL或MRI分期T3的局部晚期前列腺癌患者,淋巴结需小于20 mm。
- 患者按2:1随机分配接受ELAP或EL治疗24周后行根治性前列腺切除术,所有标本行中心病理复核。
- 主要终点为病理完全缓解或微小残留病(残留肿瘤≤5 mm),次要终点包括PSA、手术分期、切缘阳性和安全性。
- 共75例患者在四个中心入组,多数(n=65;87%)按美国国家综合癌症网络标准为高危疾病。
主要发现
- ELAP组病理完全缓解或微小残留病率为30%(15/50),EL组为16%(4/25),双侧P=0.263。
- 两组ypT3疾病、切缘阳性和淋巴结阳性率相似。
- 治疗耐受良好;两组残留肿瘤中ERG、PTEN、雄激素受体PSA和糖皮质激素受体表达水平相当。
- 肿瘤ERG阳性和PTEN缺失与根治性前列腺切除术后更广泛的残留肿瘤相关。
关键数值与推荐
- 主要终点病理完全缓解或微小残留病率:ELAP组30%(15/50)vs EL组16%(4/25),双侧P=0.263。
- 高危疾病比例:65/75(87%)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 需更长随访评估治疗对复发率的影响。
- ERG和PTEN改变与更差结局的潜在关联需额外研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locally advanced prostate cancer have an increased risk of cancer recurrence and mortality. In this phase II trial, we evaluate neoadjuvant enzalutamide and leuprolide (EL) with or without abiraterone and prednisone (ELAP) before radical prostatectomy (RP) in men with locally advanced prostate cancer. PATIENTS AND METHODS: Eligible patients had a biopsy Gleason score of 4 + 3 = 7 or greater, prostate-specific antigen (PSA) greater than 20 ng/mL, or T3 disease (by prostate magnetic resonance imaging). Lymph nodes were required to be smaller than 20 mm. Patients were randomly assigned 2:1 to ELAP or EL for 24 weeks followed by RP. All specimens underwent central pathology review. The primary end point was pathologic complete response or minimal residual disease (residual tumor ≤ 5 mm). Secondary end points were PSA, surgical staging, positive margins, and safety. Biomarkers associated with pathologic outcomes were explored. RESULTS: Seventy-five patients were enrolled at four centers. Most patients had high-risk disease by National Comprehensive Cancer Network criteria (n = 65; 87%). The pathologic complete response or minimal residual disease rate was 30% (n = 15 of 50) in ELAP-treated patients and 16% (n = four of 25) in EL-treated patients (two-sided P = .263). Rates of ypT3 disease, positive margins, and positive lymph nodes were similar between arms. Treatment was well-tolerated. Residual tumors in the two arms showed comparable levels of ERG, PTEN, androgen receptor PSA, and glucocorticoid receptor expression. Tumor ERG positivity and PTEN loss were associated with more extensive residual tumors at RP. CONCLUSION: Neoadjuvant hormone therapy followed by RP in locally advanced prostate cancer resulted in favorable pathologic responses in some patients, with a trend toward improved pathologic outcomes with ELAP. Longer follow-up is necessary to evaluate the impact of therapy on recurrence rates. The potential association of ERG and PTEN alterations with worse outcomes warrants additional investigation.
引用
- McKay RR, Ye H, Xie W, et al. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019. PMID: 30811282. doi:10.1200/JCO.18.01777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。